| Description | Neohesperidin (NSC-31048) with antioxidant and neuroprotective properties. Unlike other citrus flavanones, it does not inhibit oral carcinogenesis in a rat model. |
| In vivo | Neohesperidin (50 mg/kg) markedly inhibits 55.0% of HCl/ethanol-induced gastric lesions. In pylorus ligated rats, neohesperidin (50 mg/kg) significantly decreases the volume of gastric secretion and gastric acid output, and increases the pH[1]. Treatment of neohesperidin significantly decreases fasting glucose, serum glucose, and glycosylated serum protein (GSP) in mice. It significantly elevates oral glucose tolerance and insulin sensitivity and decreases insulin resistance in the diabetic mice. Neohesperidin significantly decreases serum triglycerides, total cholesterol, leptin level, and liver index in the mice[3]. |
| Synonyms | Hesperetin 7-O-neohesperidoside, NSC 31048, 新橙皮苷 |
| molecular weight | 610.56 |
| Molecular formula | C28H34O15 |
| CAS | 13241-33-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 50 mg/mL (81.89 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Lee JH, et al. Phytother Res, 2009, 23(12), 1748-1753. 2. Johnston K, et al. FEBS Lett, 2005, 579(7), 1653-1657. 3. Jia S, et al. Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice. Food Funct. 2015 Mar;6(3):878-86. |